A Phase 1 Dose-Escalation Study of SCH 900776 in Combination With Cytarabine in Subjects With Acute Leukemias (Protocol No. P05247)

Trial Profile

A Phase 1 Dose-Escalation Study of SCH 900776 in Combination With Cytarabine in Subjects With Acute Leukemias (Protocol No. P05247)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2017

At a glance

  • Drugs MK 8776 (Primary) ; Cytarabine
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
  • Focus Adverse reactions
  • Sponsors Merck & Co
  • Most Recent Events

    • 10 Dec 2011 Results have been reported at the 53rd Annual Meeting and Exposition of the American Society of Hematology.
    • 15 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Apr 2011 Planned end date changed from 1 May 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top